Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

Concepts (127)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colonic Neoplasms
3
2016
158
0.790
Why?
Anus Neoplasms
1
2018
24
0.610
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2020
994
0.530
Why?
Bone Marrow Neoplasms
1
2015
12
0.520
Why?
Embolism
1
2015
20
0.520
Why?
Gene Regulatory Networks
1
2016
107
0.500
Why?
Carcinoma, Squamous Cell
1
2018
330
0.490
Why?
Tumor Lysis Syndrome
1
2014
5
0.490
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2014
53
0.470
Why?
Neoplasm Recurrence, Local
1
2018
626
0.460
Why?
Pyrazoles
1
2014
111
0.450
Why?
Pyrimidines
1
2014
192
0.430
Why?
Angiogenesis Inhibitors
2
2006
182
0.430
Why?
Clinical Trials as Topic
5
2019
466
0.420
Why?
Salvage Therapy
1
2013
136
0.420
Why?
Biliary Tract Diseases
1
2012
12
0.420
Why?
Actinomycosis
1
2012
10
0.420
Why?
Bile Duct Neoplasms
1
2012
28
0.410
Why?
Stomach Neoplasms
1
2015
187
0.410
Why?
Prognosis
6
2019
1956
0.380
Why?
Gene Expression Profiling
1
2016
1028
0.380
Why?
Benzenesulfonates
2
2011
10
0.370
Why?
Middle Aged
12
2020
12289
0.370
Why?
Carcinoma, Hepatocellular
1
2013
194
0.360
Why?
Stroke
1
2015
478
0.360
Why?
Pyridines
2
2011
133
0.340
Why?
Liver Neoplasms
1
2013
329
0.330
Why?
Colorectal Neoplasms
2
2003
253
0.320
Why?
Aged, 80 and over
6
2018
3137
0.300
Why?
Heparin
1
2007
92
0.280
Why?
Drug Industry
1
2007
38
0.280
Why?
Thrombocytopenia
1
2007
79
0.280
Why?
Communication Barriers
1
2007
32
0.280
Why?
Hypertensive Encephalopathy
1
2006
3
0.280
Why?
raf Kinases
1
2006
4
0.280
Why?
Thiazolidinediones
1
2007
82
0.270
Why?
Aged
9
2020
9448
0.260
Why?
Anticoagulants
1
2007
254
0.240
Why?
Thrombosis
1
2007
249
0.240
Why?
Skin
1
2007
415
0.240
Why?
Adult
9
2020
13355
0.230
Why?
Enzyme Inhibitors
1
2006
378
0.230
Why?
Female
11
2020
26571
0.230
Why?
Survival Rate
2
2018
905
0.220
Why?
Prostatic Neoplasms
1
2007
391
0.220
Why?
Humans
16
2020
49922
0.220
Why?
Follow-Up Studies
3
2019
2177
0.210
Why?
Camptothecin
1
2002
16
0.200
Why?
Male
10
2020
25450
0.200
Why?
Antineoplastic Agents, Phytogenic
1
2002
67
0.190
Why?
Lung Neoplasms
1
2007
601
0.190
Why?
Diabetes Mellitus, Type 2
1
2007
483
0.180
Why?
Oximes
1
2020
13
0.180
Why?
Pyrimidinones
1
2020
18
0.180
Why?
Pyridones
1
2020
35
0.180
Why?
Thalidomide
1
2002
374
0.170
Why?
Imidazoles
1
2020
128
0.170
Why?
Cholangiocarcinoma
2
2011
26
0.160
Why?
Protein Kinase Inhibitors
1
2020
205
0.160
Why?
Survival Analysis
3
2020
670
0.150
Why?
Antineoplastic Agents
2
2019
1175
0.150
Why?
Melanoma
1
2020
281
0.140
Why?
Combined Modality Therapy
1
2018
638
0.130
Why?
Neoplasm Staging
2
2013
749
0.130
Why?
Severity of Illness Index
1
2019
953
0.130
Why?
Antibodies, Monoclonal
1
2019
457
0.120
Why?
Skin Neoplasms
1
2020
487
0.120
Why?
Gene Amplification
1
2015
57
0.120
Why?
Adenine
1
2014
31
0.120
Why?
Polycomb Repressive Complex 2
1
2015
46
0.120
Why?
Retrospective Studies
3
2018
6124
0.120
Why?
Genes, myc
1
2015
40
0.120
Why?
United States
3
2019
4880
0.120
Why?
Piperidines
1
2014
96
0.110
Why?
Gene Deletion
1
2015
267
0.110
Why?
Registries
3
2007
523
0.110
Why?
Treatment Outcome
4
2020
5178
0.110
Why?
Quinazolines
1
2013
32
0.110
Why?
Leukemia, Myeloid, Acute
1
2015
179
0.110
Why?
Actinomyces
1
2012
9
0.100
Why?
Gene Expression Regulation, Neoplastic
1
2016
824
0.100
Why?
Endoscopy, Gastrointestinal
1
2012
76
0.100
Why?
Comorbidity
2
2019
610
0.100
Why?
Gallbladder Neoplasms
1
2011
7
0.100
Why?
Antibodies, Monoclonal, Humanized
1
2013
223
0.100
Why?
Phenylurea Compounds
2
2011
15
0.090
Why?
Niacinamide
2
2011
23
0.090
Why?
Incidence
2
2019
986
0.090
Why?
Neoplasms
1
2019
1234
0.080
Why?
Drugs, Investigational
1
2007
14
0.070
Why?
Necrosis
1
2007
175
0.070
Why?
Causality
1
2007
45
0.070
Why?
Hospitals, University
1
2007
77
0.070
Why?
Confidence Intervals
1
2007
154
0.070
Why?
Tomography, X-Ray Computed
1
2012
1153
0.070
Why?
Probability
1
2007
163
0.070
Why?
Age Distribution
1
2007
169
0.070
Why?
Neoplasm Metastasis
2
2011
235
0.070
Why?
United States Food and Drug Administration
1
2007
91
0.070
Why?
Anti-Bacterial Agents
1
2012
742
0.070
Why?
Medical Oncology
1
2007
95
0.070
Why?
Syndrome
1
2006
237
0.060
Why?
Patient Selection
1
2007
254
0.060
Why?
Publication Bias
1
2005
11
0.060
Why?
Editorial Policies
1
2005
11
0.060
Why?
Periodicals as Topic
1
2005
57
0.060
Why?
Dose-Response Relationship, Drug
1
2007
1354
0.060
Why?
Risk Assessment
1
2007
1254
0.050
Why?
MAP Kinase Kinase Kinases
1
2020
19
0.050
Why?
Socioeconomic Factors
1
2003
584
0.040
Why?
Proto-Oncogene Proteins B-raf
1
2020
78
0.040
Why?
Mutation, Missense
1
2020
103
0.040
Why?
Drug Administration Schedule
1
2020
369
0.040
Why?
Trisaccharides
1
2019
1
0.040
Why?
Premedication
1
2019
18
0.040
Why?
Administration, Oral
1
2020
433
0.040
Why?
Magnetic Resonance Imaging
1
2006
1526
0.040
Why?
Infusions, Intravenous
1
2019
212
0.040
Why?
Antibodies
1
2019
151
0.040
Why?
Health Services Accessibility
1
2003
417
0.040
Why?
Disease Management
1
2019
175
0.040
Why?
Arkansas
1
2003
1989
0.030
Why?
Adolescent
1
2007
6416
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
256
0.030
Why?
Polymorphism, Single Nucleotide
1
2015
482
0.030
Why?
Young Adult
1
2020
4031
0.020
Why?
Disease-Free Survival
1
2011
450
0.020
Why?
Govindarajan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description